Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Q3 FY24 Earnings Presentation
25 slides from Anupam Rasayan India's earnings presentation, Feb 12, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
ANUPAM RASAYAN INDIA LTD. R ARILSLDSTX20240212115 Date: February 12, 2024 To, To, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai -400001, India Mumbai 400051, India SCRIP CODE:
Slide 2: Anupam Rasayan India Limited Q3FY24 February 2024
Anupam Rasayan India Limited Q3FY24 FEBRUARY 2024
Slide 3: Quarterly Highlights
Quarterly Highlights 1 2 Anupam Rasayan India Limited \
Slide 4: Quarterly Financial Highlights
3 Quarterly Financial Highlights \ Limited India Consolidated EBITDA (Incl. Consolidated PAT stood Rasayan Consolidated Total Revenue was ₹ 2,979 Mn; Other Revenue) was ₹ 815 Mn.; at ₹ 260 Mn., margin Y-o-Y de-growth of 23% margin stands at 27% stands at 9% Anupam Standalone Total Revenue Standalone
Slide 5: Managing Director's Message
4 Managing Director’s Message \ Limited “The chemical industry continues to face headwinds impacting our performance for the India quarter. This, coupled with client off-taking minimum required quantities to manage their year-end working capital has led to degrowth in our revenues for the quarter. E
Slide 6: Operational Updates
5 Operational Updates \ Limited India Commercialization of New Molecules – In Q3FY24, 6 new molecules were commercialized taking total to 11 new molecules launched in 9MFY24. Of the total 6 molecules, 4 molecules were from fluorination series and 2 molecules from signed LOIs and Rasayan contracts. A
Slide 7: Consolidated Profit & Loss Summary Q3FY24
6 QUARTERLY FINANCIALS Consolidated Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) Q3FY24 Q3FY23 INCOME India Revenue from Operations 2,955 3,921 Other Income 24 (33) Rasayan Total Revenue 2,979 3,888 Total Revenue Growth (%) (23)% EXPENSES: Anupam Cost of Raw Materials Consumed 1,009 1,6
Slide 8: Standalone Profit & Loss Summary Q3FY24
7 QUARTERLY FINANCIALS Standalone Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) Q3FY24 Q3FY23 INCOME India Revenue from Operations 2,147 2,955 Other Income 14 (44) Rasayan Total Revenue 2,161 2,912 Total Revenue Growth (%) (26%) EXPENSES: Anupam Cost of Raw Materials Consumed 574 1,115 G
Slide 9: Consolidated Profit & Loss Summary 9MFY24
8 NINE MONTH FINANCIALS Consolidated Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) 9MFY24 9MFY23 INCOME India Revenue from Operations 10,741 11,219 Other Income 182 (157) Rasayan Total Revenue 10,923 11,062 Total Revenue Growth (%) (1%) EXPENSES: Anupam Cost of Raw Materials Consumed 4,2
Slide 10: Standalone Profit & Loss Summary 9MFY24
9 NINE MONTH FINANCIALS Standalone Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) 9MFY24 9MFY23 INCOME India Revenue from Operations 8,202 9,128 Other Income 148 (158) Rasayan Total Revenue 8,351 8,970 Total Revenue Growth (%) (7%) EXPENSES: Anupam Cost of Raw Materials Consumed 2,911 3,3
Slide 11: Business Overview
Business Overview 2 10 Anupam Rasayan India Limited \
Slide 12: Company at a glance
11 Innovating Sustainable & Custom Solutions for Global Markets \ Limited Company at a glance India Established Custom Specializes in multi-step Catering to globally Strong supply chain Synthesis player with 40 synthesis undertaking relevant chemical & with backward Rasayan years of track record com
Slide 13: Evolution of Anupam
12 Evolution of \ Phase II- Limited Phase I-Inception Anupam The Acceleration India • Raised ₹5,000 mn. through QIP Formed Rasayan • Commissioned Solar partnership firm Power Plant of 5.4MW “Anupam Rasayan” at Bharuch • Fast growing Anupam Specialty Chemical Acquired ~26% Manufacturer with Started s
Slide 14: Chemical Conduits and Global Partnerships
13 Chemical Conduits and Global Partnerships \ Limited India Business Verticals Overview Few of our top global clients Geography-Wise Revenue Rasayan Life Science Related Other Specialty Specialty Chemicals Chemicals FY23 EUROPE 30% INDIA 36% Agrochemicals Anupam Specialty Pigments SINGAPORE 12% (in
Slide 15: Charting New Frontiers with R&D Excellence
14 Charting New Frontiers with R&D Excellence \ Limited Process technologies deployed India Flow Chemistry Photo Chemistry • Reduced lead time • Simplified Rasayan • Material efficient & synthesis of cost benefits complex molecules • Lesser • Larger potential for environmental automation impacts in
Slide 16: Experienced Leadership & Deep Technical Talent Pool
15 Experienced Leadership & Deep Technical Talent Pool \ Limited Experienced management team Mr. Gopal Agrawal Mr. Ravi Desai India Chief Executive Officer Sales Head Qualified CA with 25+ yrs. Exp in 20+ years of experience; with Corporate Strategy, global M&A and ARIL since 2012 Rasayan Mgmt Consu
Slide 17: Expanded Business Development Team Globally
16 Expanded Business Development Team Globally \ Limited Europe United States India Mr. Thierry Baumlin Mr. Pierre Joris Mr. John Grant Rasayan Key Account Manager - Business Advisor - Business Advisor - Crop Protection Specialty Fluoro Chemicals Specialty Fluoro Chemicals 30 years+ of experience in
Slide 18: Growth Drivers
Drivers Growth 3 17 Anupam Rasayan India Limited \
Slide 19: Growth Drivers
18 Growth Drivers \ Limited India Rasayan 1 2 3 Anupam Growth of Execution of Expansion in Product Signed LOIs and Fluorination Portfolio Contracts chemistry
Slide 20: Growth Of Product Portfolio
19 Growth Of Product Portfolio \ Limited New Strategic Custom 90+ 11+ India Development Products under pipeline to be manufactured by Number of molecules Number of molecules to be Rasayan Anupam in India: in R&D and Pilot commercialised in FY24 Anupam Agro Pharma • Established Active Ingredients of
Slide 21: Strong Order Book – Recent LOI/Contracts Signed
20 Strong Order Book – Recent LOI/Contracts Signed \ Limited Signing Quarter Segment Customer LOI/Contract Tenor (Years) Value(₹ Crores) India Q1FY22 Life Science Multinational Life Science Company LOI 5 ₹1,100 Q1FY22 Life Science Two Multinational Companies Contract 5 ₹540 Rasayan Q2FY22 Life Scien
Slide 22: Strategic Expansion in Fluorination with Tanfac
21 Anupam’s Strategic Expansion in Fluorination with Tanfac \ Limited Anupam acquired ~26% stake in India Tanfac for ~₹1,530M in May'22 Rasayan Producer of Leading Anupam fluorinated producer of intermediates KF/HF • Specialty fluoride chemical Anupam Tanfac manufacturer in India Only Indian • Leadi
Slide 23: Expansion in Fluorination Chemistry
22 Expansion in Fluorination Chemistry \ Limited FOCUSED SEGMENTS MOLECULES END APPLICATION CUSTOMER SEGMENT REVENUE India POTENTIAL Product A Elastomer US MNC Rasayan Polymers $ 40 – 70 Mn. Product B Semiconductor/Flame Retardant Japanese MNC Anupam Product X/Y Cardio/Anti-viral Indian MNC Pharmace
Slide 24: Summary: Strengths and Key Highlights
23 Summary \ Limited Strengths and Key Highlights India • Doubled manufacturing capacity in the last three years Rasayan Manufacturing • Strong capex plans to expand capacity into newer Prowess molecules / chemistries Anupam R&D • DSIR recognized R&D center with a team of 88 R&D professionals Capabi
Slide 25: Thank You
Corporate Office ANUPAM Anupam Rasayan India Ltd. India (HQ) 10th Floor, Icon Rio, Dumas Road, Surat, Gujarat, RASAYAN INDIA India – 395 007 LIMITED ThankYou BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 ©2022 – Anupam Rasayan India Limited, All Rights Reserved. DRAFT